BREAKTHROUGHS IN FIGHTING AGE RELATED DISEASE

 

Investor PDF Print E-mail

 

Stock Data

 

OTC Market Tier: OTCQB
Primary SIC - Industry Classification: 2834 - Pharmaceutical preparations
State Of Incorporation: NV
Jurisdiction Of Incorporation: United States
Reporting Standard: U.S. Registered & Reporting: SEC Filer
CIK: 0001434893
Fiscal Year End: 12/31
Estimated Market Cap: $226,775,640 as of Jul 13, 2010
Outstanding Shares: 188,979,700 as of Jan 12, 2010
Current Capital Change: shs increased by 91 for 1 split
Ex-Date: Jan 12, 2010
Record Date: Dec 9, 2009
Pay Date: Jan 11, 2010
Dividends: Div: 91-1 stk; Due Bill
Redeemable Date: 01/14/2010
Ex-Date: Jan 12, 2010
Record Date: Dec 9, 2009
Pay Date: Jan 11, 2010
Transfer Agent: Island Stock Transfer
100 Second Avenue South
Suite 705S
St. Petersburg, FL 33701

 

Board Of Directors

Patrick S. Smith - Chairman of the Board
David J. Corcoran - Director
Sheldon Goldberg
Father William E. McConville
Ronald Pompeo

Sheldon Goldberg

Sheldon Goldberg has been a director since February 2006. Mr. Goldberg previously served as Senior Vice President of Development for Curaxis and also served as President and Chief Executive Officer of the Alzheimer’s Association, a patient advocacy group for Alzheimer’s disease. From September 1999 to May 2005, Mr. Goldberg also served as Chairman of the Board of AARP Services Inc. a subsidiary of AARP which markets products and services to AARP members. From October 1995 to October 2002, Mr. Goldberg served as President and Chief Executive Officer of the Jewish Home and Hospital Lifecare Systems in New York, a long-term care health provider. Mr. Goldberg is a graduate of the University of the Wisconsin.

Father William E. McConville

Father William E. McConville has been a director since February 2006. Since September 2001, Father McConville has been associate pastor for St. Francis of Assisi. From July 1989 to June 2001, he was a professor of religious studies at Sienna College. Father McConville has served as a member of the boards of directors and board of trustees of various educational and charitable institutions. Father McConville is a graduate of Catholic University of America and received his M.A. in Theology from Washington Theological Union and his Ph.D. in Systematic Theology from Vanderbilt University. Father McConville is a member of the Order of Friars Minor.

Ronald Pompeo

Ronald Pompeo has been a director since July 2009. Mr. Pompeo is a long-time shareholder of Curaxis and is President and CEO of Rudy V. Pompeo, Inc., a general construction contractor based in Weymouth, Massachusetts. In addition, Mr. Pompeo is active in a number of volunteer and not for profit organizations. He is a graduate of Boston College.

Special Advisor to the Chairman

Tommy G. Thompson

Since February 2005, Secretary Thompson has been a partner in Akin Gump Strauss Hauer & Feld LLP, a law firm. From February 2001 to January 2005, Secretary Thompson served as Secretary of the Department of Health and Human Services under President George W. Bush. From 1987 to February 2001, Secretary Thompson served as Governor of the State of Wisconsin. Secretary Thompson has received numerous public service awards, including The Anti-Defamation League’s Distinguished Public Service Award, Governing Magazine’s Public Official of the Year Award, and the Horatio Alger Award. The Secretary has served as chairman of the National Governors’ Association, the Education Commission of the States and the Midwestern Governors’ Conference. Mr. Thompson serves as a member of the board of directors of C.R. Bard, Inc., a surgical and medical instruments company, and Centene Corporation, a managed care organization. Secretary Thompson is a graduate of, and received his law degree from, The University of Wisconsin-Madison.

 

Partnerships

Curaxis has engaged a very impressive infrastructure of scientific/technical, medical and legal advisers as strategic partners. This allows the Company to leverage talented individuals who provide key knowledge, expertise and support. A selection of these partnerships is represented by:

• Our collaboration in discovery research with leading Alzheimer's research teams led by George Perry, PhD, Mark A. Smith, PhD (www.cwru.edu/med/pathology);
• Leading patent and FDA legal support from Covington & Burling (www.cov.com);
• Clinical and FDA regulatory support from Bert Spilker & Associates (www.bertspilker.com);
• Drug development and delivery support from DURECT Corporation (www.durect.com);
• Investor Relations and communications support by Groupmark Financial Services Ltd. (www.groupmarkltd.com)

Case Western Reserve University - Department of Pathology

World-class research is conducted in the Department of Pathology with major emphasis on the following areas and more: cancer biology, infection and immunity, neurobiology/neuropathology, tissue injury and healing, and biomaterials biocompatibility. These emphasis areas are reflected in the three tracks of the Pathology Graduate Program: the Cancer Biology Training Program (CBTP), the Immunology Training Program (ITP) and the Molecular and Cellular Basis of Disease Training Program (MCBDTP). The Pathology Graduate Program provides extensive opportunities for PhD or MD-PhD training in these areas. A separate program leads to the MS degree.

Covington & Burling LLP

Covington & Burling LLP represents clients in cutting-edge technology, litigation, white collar defense, transactional, governmental affairs, international, life sciences and other matters. In responding to the needs and challenges of our clients, our lawyers draw upon the firm’s expertise and experience in a broad array of industries to provide solutions to difficult, complex, and novel problems and issues, whether in litigation, transactions, or regulatory proceedings.

Bert Spilker & Associates

The mission of Bert Spilker & Associates (BS&A) is to provide clients with the highest quality, most cost-effective, and timely pharmaceutical consulting services available. To achieve this goal, Bert has assembled a group of over 150 independent associates who are available to assist him in most aspects of drug discovery, drug development and strategy setting. BS&A strives to build long-term relationships with clients based on knowledge of his clients culture, research, products and services.

Groupmark Financial, Ltd.

Groupmark is a privately owned, global Corporate Consulting and Investor Relations company. Combining unparalleled experience, comprehensive capabilities across all industries and business functions, and extensive research on the world’s most successful companies, Groupmark collaborates with clients to help them become high-performance businesses.

Groupmark’s team of dedicated professionals is made up of individuals with diverse experience from a variety of business specialties and financial fields. The team has worked together on mergers and acquisitions, private equity transactions, IPO listings, joint venture proceedings, cross-border strategic partnerships, professional services and investor relations. The team is multilingual (English, Mandarin Chinese, Japanese, French and German) and is equally versed in Eastern and Western business culture and ethics.

 

Email Updates





Curaxis Pharmaceutical is engaged in the business of developing therapies for the treatment of Alzheimer’s Disease and age related illness.